SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is trending as the community anticipates potential impacts from a new ETF, with some seeing it as a legitimizing factor and a catalyst for price appreciation. Community members are actively discussing potential price targets and long-term holding strategies. There is excitement around potential gains and the coin's long-term prospects within the broader crypto market.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

PEPE.X is trending as the community speculates on potential rallies and discusses strategies to push the price higher, with some eyeing the possibility of revisiting all-time highs. Community members are actively sharing bullish sentiments and engaging in meme-based discussions, while also debating the token's potential within the broader meme coin landscape, comparing it to other popular cryptocurrencies like DOGE.X and SHIB.X.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media is trending amidst heated discussions and political division following the tragic death of Charlie Kirk, a prominent conservative figure; community members are grappling with the suspect's background and motives, with intense debate over his political affiliations and the broader implications for political discourse; the stock is also drawing attention within the context of ongoing debates around free speech, political violence, and the influence of media narratives.

Bonk is the first Solana dog coin for the people, by the people with 50% of the total supply airdropped to the Solana community. The Bonk contributors were tired of toxic “Alameda” tokenomics and wanted to make a fun memecoin where everyone gets a fair shot.

BONK

BONK.X is trending as the community anticipates a potential token burn event upon reaching 1 million holders, driving excitement and speculation. Discussions revolve around overcoming resistance levels and the possibility of new exchange listings, further fueling interest in the meme coin within the Solana ecosystem. Bullish sentiment is growing, with some suggesting it could be the start of an altcoin run.

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Atyr Pharma Inc

aTyr Pharma, Inc

aTyr Pharma ($ATYR) is trending as investors eagerly await Phase 3 trial results for its lead drug, efzofitimod, aimed at treating pulmonary sarcoidosis; the data is anticipated to come out mid September, though some believe it will be sooner. Community discussions revolve around potential outcomes, with both bullish expectations of a short squeeze and bearish concerns about trial success. Chatter is fueled by recent analyst ratings and company hiring moves, with an increase in option activity and a wide implied move.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

Kendu is trending as community members highlight its strong holder distribution and growing community, emphasizing the project's focus on real-world applications and brand building. The community is excited about new initiatives and partnerships, reinforcing the project's long-term vision. Discussion also centers around the potential for significant growth, with many expressing bullish sentiment.

Shiba Inu (SHIB) is a meme token which began as a fun currency and has now transformed into a decentralized ecosystem. During the initial launch, 50% of the supply was allocated into Vitalik Buterin's ethereum wallet.   As a result of that, Vitalik proceeded to donate 10% of his SHIB holdings to a COVID-19 relief effort in India and the remaining 40% is burnt forever. That donation was worth about $1 billion at that time, which makes it one of the largest donation ever in the world.  What is the Shiba Inu community working on right now? The Shiba Inu team launched a decentralized exchange called Shibaswap with 2 new tokens, LEASH and BONE. LEASH is a scarce supply token that is used to offer incentives on Shibaswap. BONE is the governance token for holders to vote on proposals on Doggy DAO.

Shiba Inu

Shiba Inu is trending with community members expressing both bullish sentiment and frustration with lagging price action compared to other meme coins like Doge. Some traders are speculating on potential breakouts while others are pointing to the large token supply as a limiting factor. Talk of a Shib stablecoin and Asian market expansion is also circulating.

Velodrome Finance

VELOD.X is trending due to increased discussion around its potential within the Optimism superchain ecosystem and comparisons to AERO.X, with some traders anticipating a similar breakout. Recent integrations and listings, like Kraken, are also being highlighted as potential catalysts for future growth, while others point to a Binance listing pump and dump.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending as community members discuss its potential to reach new all-time highs, fueled by bullish indicators and significant investments from firms like Galaxy Digital. The buzz around Solana-based meme coins and potential treasury plays is also contributing to the heightened interest. Some users are also speculating about the possibility of Solana ETFs.

The ODP Corp. is a holding company, which engages in the provision of business services and supplies, products, and digital workplace technology solutions. It operates through the following segments: ODP Business Solutions Division, Office Depot Division, and Veyer Division. The ODP Business Solutions Division acts as a B2B distribution solutions provider serving small, medium, and enterprise level companies, including those in the public and education sectors. The Office Depot Division offers retail consumer and small business products and services distributed through a fully integrated omni-channel platform of 869 Office Depot and OfficeMax retail. The Veyer Division consists of supply chain, distribution, procurement, and global sourcing operation, which specializes in B2B and consumer business service delivery, with core competencies in distribution, fulfillment, transportation, global sourcing and purchasing. The company was founded in 1986 and is headquartered in Boca Raton, FL.

ODP Corporation (The)

ODP is trending as the community discusses a potential cultural boycott following a reported incident at an Office Depot location.  Some community members are expressing intentions to cancel corporate accounts and sell short based on the perception that the company is alienating a portion of its customer base, while others are defending the company. The stock's broader context includes transformation efforts to focus on B2B, with potential for volatility amidst the ongoing discussions.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Sagimet Biosciences Inc. (SGMT) Upgraded to Buy: What Does It Mean for the Stock?

Sagimet Biosciences Inc. (SGMT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

After Plunging 28% in 4 Weeks, Here's Why the Trend Might Reverse for Sagimet Biosciences Inc. (SGMT)

The heavy selling pressure might have exhausted for Sagimet Biosciences Inc. (SGMT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

What Makes Sagimet Biosciences Inc. (SGMT) a Strong Momentum Stock: Buy Now?

Wall Street Analysts Predict a 437.05% Upside in Sagimet Biosciences Inc. (SGMT): Here's  What You Should Know

Shares of Sagimet Biosciences soared nearly 40% on Monday, reaching levels not seen since March 2024, as retail sentiment surged following news of an upcoming presentation linked to its lead drug candidate.&nbsp;The clinical-stage biopharma company, which is developing novel therapeutics targeting metabolic and fibrotic diseases, announced that it will present at the 9th Annual MASH-TAG Conference in Park City, Utah, from Jan. 9&nbsp;to 11.The presentation will spotlight the company’s lead drug candidate, denifanstat, an oral, once-daily fatty acid synthase (FASN) inhibitor, which has shown promising results in the Phase 2b FASCINATE-2 study for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).&nbsp;<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/SGMT_sentiment_and_message_volume_Jan_6_fc5e3fb3e0.png" alt="SGMT sentiment and message volume Jan 6.png" width="1318" height="324"><figcaption>SGMT sentiment and message volume Jan 6 as of 11:35 am ET | source: Stocktwits</figcaption></figure>Retail sentiment on Stocktwits turned ‘extremely bullish,’ with Sagimet’s stock trending among the top 20 tickers as of mid-morning.&nbsp;Many investors&nbsp;eagerly await further announcements at the conference, with some buying based on rumors of a significant update.<stembedurl>https://stocktwits.com/GXD_Texas/message/598950606</stembedurl><stembedurl>https://stocktwits.com/valueforme/message/598944787</stembedurl>The study demonstrated a positive anti-fibrotic effect, providing strong support for the drug’s potential in treating liver diseases caused by excessive fat buildup and inflammation.Sagimet’s FASN inhibitors aim to address the dysfunctional metabolic pathways responsible for the overproduction of palmitate, a fatty acid linked to diseases like MASH.&nbsp;Denifanstat’s progress has been noteworthy, with Breakthrough Therapy designation granted by the FDA for treating non-cirrhotic MASH with moderate to advanced liver fibrosis (F2-F3).Oppenheimer’s recent coverage of Sagimet with an ‘outperform’ rating and a $30 price target, which implies more than a 340% upside from current levels, has also contributed to the stock’s upward movement.&nbsp;The brokerage firm highlighted denifanstat’s potential in the MASH market, which is currently dominated by Madrigal Pharmaceuticals’ Resmetirom.&nbsp;Oppenheimer estimates denifanstat could achieve peak revenues of around $1.9 billion by 2040, solidifying its long-term growth prospects.<a href="https://stocktwits.com/symbol/SGMT">Sagimet stock</a> has gained nearly 50% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Sagimet Stock Soars To 10-Month High, Retail’s Fired Up Over Presentation On Lead MASH Drug Candidate

Many investors eagerly await further announcements at the conference, with some buying based on rumors of a significant update.

Equity

Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne

Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily...

Analysts Offer Insights on Healthcare Companies: Liquidia Technologies (LQDA) and Sagimet Biosciences, Inc. Class A (SGMT)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Liquidia Technologies (LQDA Research Report) and Sagimet Biosciences, Inc. Class A...

Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives $41.50 Average PT from Analysts

Sagimet Biosciences Inc. (NASDAQ:SGMT - Get Free Report) has received an average rating of "Buy" from the six analysts that are currently covering the company, MarketBeat Ratings reports. Six...

Sagimet Biosciences CEO, President & Director Acquires 553% More Stock

Even if it's not a huge purchase, we think it was good to see that David Happel, the CEO, President & Director of...

Sagimet Biosciences (NASDAQ:SGMT) PT Lowered to $27.00 at The Goldman Sachs Group

Sagimet Biosciences (NASDAQ:SGMT  Free Report) had its price objective cut by The Goldman Sachs Group from $37.00 to $27.00 in a report issued on Tuesday, Benzinga reports. They currently have...

Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.

SGMT
Sagimet Biosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest SGMT News

SGMT Sagimet Biosciences Inc